•  
  •  
 

Subject Area

Obstetrics and Gynecology

Article Type

Original Study

Abstract

Objectives To evaluate the visual and anatomical outcomes following intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration (AMD). Background Neovascular AMD is considered a principal cause of visual impairment worldwide. It is associated with choroidal neovascularization, which causes exudation that affects vision. Early clinical trials showed that intravitreal injection of anti-vascular endothelial growth factor agents is associated with significant improvement of visual outcomes in the majority of eyes. Aflibercept is an anti-vascular endothelial growth factor agent that recently gained approval for treating neovascular AMD. Patients and methods This prospective study conducted at Menoufia University Hospitals, included 60 eyes of 46 patients with treatment–naïve neovascular AMD. The patients received 3monthly aflibercept intravitreal injections. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were measured at diagnosis and after each injection. Also, the patients were asked to fill the 25-item National Eye Institute Visual Function Questionnaire at baseline and at the end of the study. Results The mean BCVA improved from 0.061 (decimal fraction) to 0.081 after the third injection (P < 0.001). The mean CMT significantly decreased from 484.07 μm at baseline to 331.1 μm after the third injection (P < 0.001). No significant changes in intraocular pressure were observed during the study. There was a significant improvement in total score and some subscale scores of the 25-item National Eye Institute Visual Function Questionnaire. Conclusion Intravitreal aflibercept in neovascular AMD is associated with increased BCVA and reduced CMT. In addition, intravitreal aflibercept possibly has a benefit of improving the quality of vision-related functions.

Download

Share

COinS